Onkologie. 2012:6(6):316-318

Systemic therapy of brain metastases

Radka Obermannová
Masarykův onkologický ústav, Brno

Brain metastases are most common in tracranial tumors in adults. They have been reported to occur in approximately 10–20 % patients

with solid malignancies. Although modern methods of anticancer therapy brought longer survival for patients with systemic disease, there

is no evidence to prolong survival in case of brain metastases. We are summarized published data.

Keywords: solid malignancies, brain metastases, systemic therapy

Published: December 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Obermannová R. Systemic therapy of brain metastases. Onkologie. 2012;6(6):316-318.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Nussbaum ES, DjalilianHR, ChoKH, et al. Brain metastases. Histology, multiplicity, surgery, and survival. Cancer 1996; 78: 1781-1788. Go to original source...
    2. Barnholtz-Sloan JS, Sloan AE, Davis FG, et al. Incidence proportionsof brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 2004; 22: 2865-2872. Go to original source... Go to PubMed...
    3. Gaspar LE, Scott C, Rotman M, Murray K, et al. Validitionofthe RTOG recursive partitioning analysis (RPA) classificationfor brain metastases. Int J Radiat Oncol Biol Phys 2000; 47: 1001-1006. Go to original source... Go to PubMed...
    4. Walbert T, Gilbert MR. The role of chemotherapy in the treatment of patients with brain metastases from solid tumors. Int J Clin Oncol 2009; 14: 299-306. Go to original source... Go to PubMed...
    5. Chamberlain MC. Anticancer therapies and CNS relapse: overcomingblood-brain and blood-cerebrospinal fluid barrier impermeability. Expert Rev. Neurother. 2010; 10(4): 547-561. Go to original source... Go to PubMed...
    6. Polli JW, OlsonKL, Chism JP, et al. An unexpected synergist role of P-glycoprotein and breast cancer resistence protein on the central nervous systém penetration of the tyrosine kinase inhibitor lapatinib, GW572016. Drug. Metab. Dispos. 2009; 37(2): 439-442. Go to original source... Go to PubMed...
    7. Mehta MP, Paleologos NA, Mikkelsen T, et al. The role ofchemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practise guideline. J Neurooncol 2010; 96: 71-83. Go to original source... Go to PubMed...
    8. Robinet G, Thomas P, Breton JL, Lena H, Gouva S, Dabouis G, et al. Resultes of the phase III study of early versus delyaed whole brain radiothery with concurrent cisplatine and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Francais de Pneumo-Cancerologie (GFPC) protocol 95-1. Ann Oncol 2001; 12(1): 59-67. Go to original source... Go to PubMed...
    9. Lee DH, Han JY, Kim HT, Yoon SJ, Pyo HR, Cho KH, et al. Primary chemotherapy for newly diagnosed nonsmall cell lung cancer patients with synchronous brain metastases compared with whole-brain radiotherapy administered first: result of a randomised pilot study. Cancer 2008; 113(1): 143-149. Go to original source... Go to PubMed...
    10. Ammirati M, Cobbs CHS, Linskey ME, et al. The role of retreatment in the management of reccurent/progressive brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010; 96: 85-96. Go to original source... Go to PubMed...
    11. Patchell RA. The management of brain metastases. Cancer Treat Rev 2003; 29(6): 533-540. Go to original source... Go to PubMed...
    12. Cameron D, Cassey M, Press M, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on transtuzumab: update defficacy and biomarker analyses. BreastCancerRes. Treat. 2008; 112(3): 533-543. Go to original source... Go to PubMed...
    13. Lin NU, Diéraz V, Paul D, et al. Multicenter phase II study of lappatinib in patients with brain metastases from Her2- positive breast cancer. Clin. Cancer Res. 2009; 15(4): 1452-1459. Go to original source... Go to PubMed...
    14. Arslan UY, Oksuzoglu B, Aksoy, et al. Breast cancer subtypes and outcomes of cetral nervous system metastases. The Breast 2011; 20: 562-567. Go to original source... Go to PubMed...
    15. Margolin KA, Di Giacomon AM, Maio M. Brain metastasis in Melanoma: Clinical Activity of CTLA-4 Antibody Therapy. Semin. Oncol 2010; 37: 468-472. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.